EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JUNE 22, 2017
Media Advisory: To contact corresponding study author Woo Kyung Moon, M.D., email firstname.lastname@example.org
To place an electronic embedded link in your story: Links will be live at the embargo time: http://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2017.1256
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Women who are treated with breast conservation surgery and radiotherapy remain at an increased risk for second breast cancers. The multicenter comparison study by Woo Kyung Moon, M.D., of the Seoul National University College of Medicine, the Republic of Korea, and coauthors included 754 women. Annual mammography, breast ultrasonography and breast MRI were performed for both conserved and contralateral (opposite) breasts during a three-year study period for a total of 2,065 mammograms, ultrasonography and MRI screenings.
The authors report 17 cancers were diagnosed and 13 of the 17 cancers were stage 0 or stage 1. The addition of MRI screening to mammography detected 3.8 additional cancers per 1,000 women over mammography alone and the addition of ultrasonography to mammography detected 2.4 additional cancers, according to the study.
Limitations of the study include there was no control group for comparison of women undergoing mammography alone. Authors also could not evaluate the cost-effectiveness and the effect of MRI or ultrasonography screening on survival benefit.
“After breast conservation therapy in women 50 years or younger, the addition of MRI to annual mammography screening improves detection of early-stage but biologically aggressive breast cancers at acceptable specificity [correctly identifying people who don’t have disease]. Results from this study can inform patient decision-making on screening methods after breast conservation therapy,” the article concludes.
For more details and to read the full study, please visit the For The Media website.
Editor’s Note: The study was funded by Bayer Korea. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.